AstraZeneca PLC (AZN)

31.13
NYSE : Health Care
Prev Close 30.53
Day Low/High 30.40 / 31.23
52 Wk Low/High 26.97 / 34.88
Avg Volume 4.94M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 77.24B
EPS 1.10
P/E Ratio 13.69
Div & Yield 1.90 (6.20%)

Latest News

Clouds With a Golden Lining: Enterprise Software Targets

Clouds With a Golden Lining: Enterprise Software Targets

As large tech groups and private sponsors shop for software companies, outfits with enterprise clients and cloud services have come into focus.

Relypsa Finally Finds Buyer, but Potential Seen For Rival Bid

Relypsa Finally Finds Buyer, but Potential Seen For Rival Bid

Shares of Relypsa are rallying after the company announced it has agreed to be acquired by Galenica Group in a $1.53B deal.

Heavy Volume And Pre-Market Movement For AstraZeneca (AZN)

Heavy Volume And Pre-Market Movement For AstraZeneca (AZN)

Trade-Ideas LLC identified AstraZeneca (AZN) as a pre-market mover with heavy volume candidate

AstraZeneca (AZN) Is Today's Storm The Castle Stock

AstraZeneca (AZN) Is Today's Storm The Castle Stock

Trade-Ideas LLC identified AstraZeneca (AZN) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate

TAGRISSO® (OSIMERTINIB) Met Primary Endpoint In Phase III 2nd-Line Lung Cancer Trial

TAGRISSO® (OSIMERTINIB) Met Primary Endpoint In Phase III 2nd-Line Lung Cancer Trial

AstraZeneca today announced that the AURA3 Phase III trial met its primary endpoint, demonstrating superior progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy.

AstraZeneca (AZN) Stock Advancing on Patent Litigation Resolution

AstraZeneca (AZN) Stock Advancing on Patent Litigation Resolution

AstraZeneca (AZN) has resolved a patent litigation with Sandoz for a hormonal therapy drug.

Theresa May to Be Appointed New U.K. Prime Minister

Theresa May to Be Appointed New U.K. Prime Minister

Corporate governance changes are among the policy flagships unveiled by the successor to David Cameron.

Heavy Early Morning Activity On AstraZeneca (AZN)

Heavy Early Morning Activity On AstraZeneca (AZN)

Trade-Ideas LLC identified AstraZeneca (AZN) as a pre-market mover with heavy volume candidate

AstraZeneca (AZN) Stock Up, Argus Research Initiates Coverage

AstraZeneca (AZN) Stock Up, Argus Research Initiates Coverage

Shares of AstraZeneca (AZN) are up today as Argus Research initiates coverage of the company with a ‘hold’ rating.

How Will AstraZeneca (AZN) Stock Be Affected by Generic Copies?

How Will AstraZeneca (AZN) Stock Be Affected by Generic Copies?

AstraZeneca’s (AZN) drug Crestor is under pressure from cheaper generic versions.

'Mad Money' Lightning Round: You Should Be Buying Visa

'Mad Money' Lightning Round: You Should Be Buying Visa

Cramer says Wynn is fantastic but he's avoiding Valeant.

Jim Cramer's 'Mad Money' Recap: Thank the Short-Sellers for This Continued Rally

Jim Cramer's 'Mad Money' Recap: Thank the Short-Sellers for This Continued Rally

When short-sellers get caught leaning the wrong way, that's a recipe for explosive moves to the upside, Cramer says.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

AstraZeneca (AZN) Moving On Heavy Pre-Market Trading

AstraZeneca (AZN) Moving On Heavy Pre-Market Trading

Trade-Ideas LLC identified AstraZeneca (AZN) as a pre-market mover with heavy volume candidate

Sanofi's Likely Sweetener for Medivation Panned

Sanofi's Likely Sweetener for Medivation Panned

The French drugmaker is reportedly thinking about including a CVR in its $9.3 billion bid for Medivation, but the move is unlikely to be enough to entice the target's shareholders.

AstraZeneca Likely to Grind Lower

Barring a strong rally over $31 that has follow-through, we look for AZN to slowly erode.

AstraZeneca, Teva Resolve Their Patent Row Over Diabetes Product

AstraZeneca, Teva Resolve Their Patent Row Over Diabetes Product

The settlement allows Teva to commercialize its generic version of Byetta in the U.S.

AstraZeneca (AZN) Leading In Pre-Market Activity

AstraZeneca (AZN) Leading In Pre-Market Activity

Trade-Ideas LLC identified AstraZeneca (AZN) as a pre-market leader candidate

Sell These 5 U.K. Stocks Now Before the Brexit Vote

Sell These 5 U.K. Stocks Now Before the Brexit Vote

Regardless of which way the vote goes, these five companies based across the pond are teetering on the edge of big potential sell signals.

'Brexit': Stocks to Avoid on June 24

'Brexit': Stocks to Avoid on June 24

Stay away from banks, but pharmaceuticals and tech stocks look good, analysts say.

Pre-Market Activity Shows Heavy Volume And Movement For AstraZeneca (AZN)

Pre-Market Activity Shows Heavy Volume And Movement For AstraZeneca (AZN)

Trade-Ideas LLC identified AstraZeneca (AZN) as a pre-market mover with heavy volume candidate

Perrigo Rises Further as Takeover Rumor Swirls

Perrigo Rises Further as Takeover Rumor Swirls

With no outright denial of the story to kill it, Perrigo's share rose further in Tel Aviv overnight on a day-old rumor of a $20 billion takeover deal.

AstraZeneca Introduces AZhelps, An Innovative Savings And Support Program To Help Patients With Their Medicines

AstraZeneca Introduces AZhelps, An Innovative Savings And Support Program To Help Patients With Their Medicines

AstraZeneca today announced it has expanded its patient support offerings to include AZhelps, a comprehensive and unique program that helps patients manage information across all their medications, access savings offers for...

Analysts' Actions -- Agios Pharma, Concho Resources, Occidental, Sprouts and More

Analysts' Actions -- Agios Pharma, Concho Resources, Occidental, Sprouts and More

Here are Monday's top research calls, including upgrades for Agios Pharmaceuticals and Concho Resources, and downgrades for Occidental Petroleum and Sprouts Farmers Market.

AstraZeneca Presents New Data From Multiple Studies On The Effect Of BYDUREON On Glucose Fluctuations In Patients With Type 2 Diabetes

AstraZeneca Presents New Data From Multiple Studies On The Effect Of BYDUREON On Glucose Fluctuations In Patients With Type 2 Diabetes

AstraZeneca today announced results from a 10-week randomized, controlled, double-blind, Phase IV study investigating the quality of glucose control with BYDUREON ® (exenatide extended-release) for injectable...